Jürgen Müllberg received a Ph.D. in Biology from RWTH Aachen in Germany. He studied molecular mechanisms of inflammation and immune modulation in both, academia and biotech. His work in biopharmaceutical firms focused on expression of therapeutic proteins and vaccines in mammalian cell culture. Currently Jürgen serves as network viral safety SME at Bristol Myers Squibb, and provides guidance on adventitious agent control and safety of manufacturing processes and cell substrates.